The Chewing Tobacco Holdout: Why America's Most Dangerous Smokeless Product Persists

The American smokeless tobacco market is dominated by products—Copenhagen, Skoal, Grizzly—that are chemically and toxicologically distinct from Swedish snus, despite sharing a superficial resemblance. American moist snuff and chewing tobacco undergo a fermentation process that generates high levels of tobacco-specific nitrosamines (TSNAs), the primary carcinogens in smokeless tobacco. Swedish snus, by contrast, is steam-pasteurized, a process that dramatically reduces TSNA levels. The difference in cancer risk is correspondingly dramatic: American smokeless products are associated with a significantly increased risk of oral cancer (odds ratios of 2-5 in most studies), while Swedish snus is not (odds ratios near 1.0, with no consistent elevation). The American smokeless market is the most dangerous segment of the non-combustible nicotine market—and it receives remarkably little regulatory attention compared to vaping or flavors.

The cultural embedding of American smokeless tobacco is deep and durable. 'Dip' and 'chew' are associated with rural identity, manual labor, military service, and certain sports (baseball, rodeo, NASCAR). The product is integrated into working-class masculine culture in ways that parallel the integration of cigarettes into broader social life. The dipper who places a wad of Copenhagen between cheek and gum after a meal, or during a long drive, or while working outdoors, is performing a ritual that has been transmitted across generations—father to son, coworker to coworker, teammate to teammate. The public health messaging that has successfully stigmatized smoking in many communities has had less impact on smokeless tobacco use, partly because the products are less visible (no smoke, no odor in the traditional sense), partly because the health risks are less well-known, and partly because the communities where smokeless use is concentrated—rural, working-class, often politically conservative—are the communities most resistant to public health messaging in general.

The tobacco industry's role in sustaining the smokeless market is less visible but equally strategic. Altria (through its US Smokeless Tobacco subsidiary, maker of Copenhagen and Skoal) and Reynolds American (through American Snuff Company, maker of Grizzly) dominate the market, which generates approximately $5 billion in annual US revenue. The smokeless business is highly profitable—margins are comparable to cigarettes, and the regulatory burden is lower (smokeless products face fewer marketing restrictions, lower taxes, and less public scrutiny). The companies have positioned smokeless products as part of a 'continuum of risk' strategy, offering smokeless as a lower-risk alternative for smokers who won't quit nicotine entirely—but the marketing of these products in practice often targets existing smokeless users rather than smokers seeking to switch. The industry's smokeless strategy is, in effect, a market-segmentation strategy: cigarettes for the urban and suburban, smokeless for the rural and working-class, with different products optimized for different market segments.

The regulatory disparity between smokeless tobacco and vaping is striking and instructive. Vaping products face intense regulatory scrutiny—PMTA requirements, flavor restrictions, marketing limitations, and continuous public controversy. American smokeless tobacco, which demonstrably causes oral cancer at rates far higher than Swedish snus or nicotine pouches, faces far less regulatory attention. The disparity reflects several factors: smokeless is an older, more established product category; it is concentrated in populations with less political influence; it does not generate the same public concern as youth vaping; and the regulatory infrastructure for smokeless tobacco is more mature (smokeless products have been regulated since the 1986 Comprehensive Smokeless Tobacco Health Education Act). The result is a regulatory environment that subjects vaping—a product category that is substantially less harmful than smoking—to stricter oversight than smokeless tobacco—a product category with well-established carcinogenic risks. The regulatory system is not organized around evidence of risk. It is organized around public salience, political pressure, and historical accident.

The public health response to smokeless tobacco has been marked by the same abstinence-only orientation that characterizes the broader tobacco control approach—with the additional complication that smokeless products have been almost entirely excluded from the harm reduction conversation. The dominant message is that 'there is no safe tobacco product' and that the only acceptable goal is complete tobacco abstinence. This message is scientifically accurate (American smokeless products are not safe) but strategically incomplete: it does not acknowledge the difference between American smokeless (carcinogenic) and Swedish snus (much less carcinogenic), it does not provide a pathway for smokeless users to transition to lower-risk alternatives, and it does not engage with the cultural and economic realities that sustain smokeless use. The smokers and smokeless users who would benefit most from honest, risk-proportionate communication about the relative risks of different nicotine products are the ones least likely to receive it—because the public health establishment has decided, as a matter of institutional policy, that the complexity of the message is not worth the risk of being misunderstood.

The path forward for smokeless tobacco regulation involves three elements: honest risk communication (acknowledging the difference between American smokeless, Swedish snus, and nicotine pouches); a regulatory framework that creates incentives for manufacturers to reduce TSNA levels (a product standard that limits TSNA concentrations would effectively transform American smokeless into something closer to Swedish snus); and integration of smokeless tobacco into the broader harm reduction conversation (recognizing that smokeless users, like smokers, can benefit from switching to lower-risk nicotine products). These are not radical proposals. They are the logical application of evidence-based public health to a product category that has been largely neglected by the evidence-based public health community.

Shareable insight: Not all smokeless tobacco is the same. American chewing tobacco causes oral cancer; Swedish snus, which is processed differently, does not—and is banned in most of Europe. The regulatory and public health systems have largely failed to communicate this distinction, with predictable consequences for the people who use the products.